Policy analysts often insist stories don’t prove policy. But when you see the pattern repeat, state after state, clinic after clinic, you stop needing theory.
The Affordable Care Act was not repealed in Congress—it was weakened in the bureaucracy. In February 2025, HHS announced it would terminate cost-sharing reduction payments, which subsidize out-of-pocket costs for lower-income ACA marketplace customers.⁴ That same month, a reinterpretation of Section 1557 of the ACA re-allowed “short-term limited-duration” health plans—insurance in name only—policies that exclude cancer care, maternity care, mental-health treatment, and prescription drugs.⁵ The administration framed them as “choice.” But as one cancer patient learned, choice is meaningless if your doctor won’t start chemotherapy without real insurance.
Her name is Michele Ray Smith, a Tampa resident interviewed in a Kaiser Family Foundation patient case archive. When her marketplace subsidy was disrupted during an administrative halt, her insurer notified her that her plan was inactive. “My doctor told me: ‘We can’t schedule chemo unless insurance is active.’ I had to wait 27 days.”⁶ The Tampa Bay Times later covered the wave of Florida patients who experienced similar sudden disruptions.⁷ Most articles never reported what happens during twenty-seven days of tumor growth. But the oncologists know.
The domestic retreat from health wasn’t limited to insurance. It extended to public-health infrastructure—the part of medicine that is invisible until it fails. CDC regional staffing fell sharply after a combination of hiring freezes and grants cut to state health departments⁸, and the Department of Homeland Security moved to limit use of federal epidemiological data-sharing that once coordinated disaster response.⁹ Surveillance slows. Outbreaks spread before they have names. And no proclamation will reverse that lost time.
But to understand what the U.S. did this year, you have to look beyond U.S. borders.
In January 2025, the United States ordered a sweeping 90-day freeze on nearly all foreign aid, including global health programs that provide HIV antiretroviral therapy, tuberculosis treatment, maternal-health support, and vaccination infrastructure—programs that reach tens of millions.¹⁰ UNAIDS warned that “treatment interruptions place millions of lives in jeopardy.”¹¹ Reuters reporting confirmed that more than 80% of USAID health programs were canceled within six weeks.¹² Staff were placed on administrative leave. An agency that normally employs 10,000 was reduced to under 300 active personnel.¹³
A USAID Office of Inspector General report warned that $8.2 billion in humanitarian aid sat unspent and without oversight, risking diversion, waste, or expiration.¹⁴ A federal judge later ordered a partial lift of the freeze, ruling that it lacked procedural justification and was actively harming humanitarian delivery.¹⁵
The damage wasn’t limited to numbers. It has a face.
In South Africa’s KwaZulu-Natal province, HIV-prevention clinics documented abrupt loss of access to PrEP, the medication that reduces HIV transmission by up to 99% when taken correctly.¹⁶ According to Reuters, **2.5 million people worldwide lost access to PrEP after donor funding was suspended.**¹⁷ UNAIDS went further: eight countries risked running out of HIV medicines entirely.¹⁸
A global study cited by Reuters found that development-aid cuts—including U.S. cuts—could contribute to 22.6 million additional deaths worldwide by 2030, including 5.4 million children under the age of five.¹⁹ Those numbers do not measure sorrow, or skill lost,